XIAP and neoplasm: Notably, cetuximab (CTX)-modified siTGF-β1@ILP exhibited stronger cytotoxicity, indicating that its active targeting ability enabled more effective siRNA delivery to tumor cells, thereby achieving better gene silencing effects.